Bliss GVS Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bliss GVS Pharma Limited reported strong financial performance for FY26 ended March 31, 2026. Standalone net profit grew 47.55% to Rs. 9,687.44 lakh from Rs. 6,565.87 lakh in FY25, while consolidated net profit increased 22.96% to Rs. 10,078.12 lakh from Rs. 8,195.91 lakh. Total standalone income rose to Rs. 70,342.41 lakh and consolidated income reached Rs. 84,621.91 lakh. The Board declared a 100% final dividend (Rs. 1 per share) subject to shareholder approval. The statutory auditor issued an unmodified (clean) opinion on both standalone and consolidated financial results. Two new subsidiaries were incorporated in Kenya and Democratic Republic of Congo during the year.
Strong profit growth signals improved operational efficiency. The clean audit opinion and consistent dividend payments indicate financial stability, which should be positive for shareholder confidence and the stock price.